Clinical and Applied Thrombosis/Hemostasis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to start reading!

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heilmann, L.
Right arrow Articles by Pollow, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heilmann, L.
Right arrow Articles by Pollow, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 2, 227-229 (2006)
DOI: 10.1177/107602960601200213

Successful Treatment of Life-threatening Bleeding after Cesarean Section with Recombinant Activated Factor VII

L. Heilmann

Department of Obstetrics and Gynecology, City Hospital Rüsselsheim, Germany

C. Wild

Department of Obstetrics and Gynecology, City Hospital Rüsselsheim, Germany

B. Hojnacki

Department of Obstetrics and Gynecology, City Hospital Rüsselsheim, Germany

K. Pollow

Department of Experimental Endocrinology, University of Mainz, Germany

Hemorrhagic shock developed in a 29-year-old nullipara without coagulopathy after emergency caesarean section. Treatment with uterotonic drugs, prostaglandins, and conservative procedures with transfusion of packed red cells and fresh-frozen plasma failed to control the diffuse vaginal and uterine bleeding. Finally an intravenous bolus injection of 90 µg/kg recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsvaerd, Denmark), was given and showed success within 20 minutes after administration, without any side effects.

Key Words: Postpartum bleeding • Emergency cesarean section • Recombinant activated factor VII • rFVIIa


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arch SurgHome page
M. Ranucci, G. Isgro, G. Soro, D. Conti, and B. De Toffol
Efficacy and Safety of Recombinant Activated Factor VII in Major Surgical Procedures: Systematic Review and Meta-analysis of Randomized Clinical Trials
Arch Surg, March 1, 2008; 143(3): 296 - 304.
[Abstract] [Full Text] [PDF]